Filament Health Corp (FLHLF) Earnings

Filament Health Corp. is a clinical-stage natural psychedelic drug development company, which engages in the discovery and development of natural psychedelic pharmaceuticals. The company is headquartered in Burnaby, British Columbia and currently employs 13 full-time employees. The Company’s platform of intellectual property enables the discovery, development, and delivery of natural psychedelic medicines. The Company’s first three botanical drug candidates are standardized, purified extracts of Psilocybe cubensis fruiting bodies include: PEX010 Psilocybin - oral delivery (1mg and 25mg), PEX020 Psilocin - oral delivery (dose withheld), and PEX030 Psilocin - sublingual delivery (dose withheld). The firm's preclinical stage drug candidates include AEX010 Ayahuasca - oral delivery (dose withheld) and AEX020 Monoamine Oxidase Inhibitor - oral delivery (dose withheld). The Company’s internal drug discovery and development program is carried out by its wholly owned subsidiary, Psilo Scientific Ltd., and is focused on developing standardized pharmaceutical-grade drug candidates from botanical psychedelic biomass.